Drug Profile
Research programme: anti-adrenomedullin monoclonal antibodies - Adrenomed
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Adrenomed
- Class Monoclonal antibodies
- Mechanism of Action Adrenomedullin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Septic shock
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for preclinical development in Septic-shock in Germany (Parenteral)
- 19 Dec 2016 Development of monoclonal antibody therapies still ongoing for Sepsis and Septic shock (Adrenomed website, December 2016)
- 19 Dec 2016 Adrenomed has issued and pending patents for anti-adrenomedullin antibodies in Europe and USA (Adrenomed website, December 2016)